GlassScriptPhysician profile
Joel C Kunze
NPI 1265418586
$9,838.86
in general payments reported to CMS, 2019-2025
55 companies · $2,497 in 2025
The $2,497 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,619 · 2022: $1,746 · 2023: $2,217 · 2024: $1,760 · 2025: $2,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,474.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,690.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,679.45 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $666.51 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $630.47 | 2021-2025 | |
| Amgen INC. | $617.05 | 2021-2025 | Otezla, Repatha, Repatha |
| Preventric Diagnostics, INC. | $541.14 | 2022 | |
| Lilly USA, LLC | $427.73 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Otsuka America Pharmaceutical, INC. | $348.17 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $330.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $234.09 | 2024-2025 | Auvelity, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $194.28 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.65 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.26 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $154.30 | 2021-2024 | Trintellix, Gattex |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.23 | 2022-2025 | Caplyta |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $126.79 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $121.06 | 2021-2023 | Spravato, Xarelto |
| Neos Therapeutics, LP | $103.01 | 2021-2025 | Adzenys Xr-Odt |
| Exact Sciences Corporation | $98.51 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $97.97 | 2022-2025 | Rexulti |
| Tris Pharma INC | $83.14 | 2021-2025 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $78.66 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $75.20 | 2021-2024 | Nexletol |
| Astellas Pharma US INC | $72.49 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $69.90 | 2023-2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $64.10 | 2022 | |
| Tolmar, INC. | $53.73 | 2025 | Jatenzo |
| Biohaven Pharmaceuticals, INC. | $53.09 | 2021 | |
| Aimmune Therapeutics, INC. | $51.50 | 2024-2025 | Zenpep |
| Abbott Laboratories | $50.69 | 2021-2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $48.75 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $45.94 | 2021-2024 | Gardasil 9, M-M-R II, Vaxelis |
| Eisai INC. | $45.16 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $40.59 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $31.25 | 2022-2023 | Gvoke Hypopen |
| Ibsa Pharma INC. | $31.21 | 2021 | |
| Amneal Pharmaceuticals LLC | $29.70 | 2023-2025 | Unithroid, Crexont |
| Amarin Pharma, INC. | $29.68 | 2021 | |
| Genentech USA, INC. | $26.32 | 2021 | |
| Azurity Pharmaceuticals, INC. | $25.47 | 2025 | Edarbi |
| Supernus Pharmaceuticals, INC. | $24.99 | 2021 | |
| Dexcom, INC. | $23.17 | 2024 | Dexcom G6 Transmitter |
| Alkermes, INC. | $21.64 | 2025 | Aristada, Lybalvi |
| Sanofi Pasteur INC. | $21.19 | 2025 | |
| Impel Pharmaceuticals INC. | $19.32 | 2023 | Trudhesa |
| Mylan Specialty L.P. | $17.50 | 2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $17.22 | 2023 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $16.66 | 2025 | Austedo Xr |
| Organon LLC | $16.51 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.51 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $15.98 | 2024 | Contrave |
| Medtronic, INC. | $15.64 | 2025 | Minimed 780g |
| Corium, LLC | $15.29 | 2025 | Azstarys |
| Almatica Pharma LLC | $13.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Kunze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.